In spite of their potential to tackle cancer in the long term, CAR-T cell therapies face challenges in terms of pricing, manufacturing and being limited to blood cancer.
Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases.
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.
Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, recently closed a US$37m Series A financing round led by Kineticos Ventures.
Kite, a Gilead company, says the US Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.
Curate Biosciences reports that City of Hope, one of the largest cancer research and treatment organizations in the US, has given a thumbs up to the company’s cell processing system for advanced cell separation.
The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.
There were 168 Advanced Therapy Medicinal Product (ATMP) trials ongoing in the UK in 2021, compared to the 154 studies reported the previous year, a 9% increase, finds a new report.
A study that reveals new understanding of Chimeric Antigen Receptor (CAR) T cell functionality is said to underscore the critical role that cell avidity or binding plays in uncovering and optimizing CAR T cells.
The selected companies, the inaugural cohort for MassBioDrive, get to participate in an eight-week program focused on growing businesses and advancing breakthrough science.
Celyad Oncology has decided to voluntarily pause dosing and enrollment of patients in the CYAD-101-002 trial in order to investigate reports of two patient deaths.
IASO Biotherapeutics and Innovent Biologics have announced that the FDA has granted Orphan Drug Designation (ODD) to their fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or...
Japan’s ministry for health has approved Abecma as a CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies.
Seattle-based Umoja Biopharma, a company looking to reprogram immune cells in-vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, has started work on its new development and manufacturing facility...
The World Health Organization (WHO), as part of its International Nonproprietary Names (INN) system, has recently made progress in developing and harmonizing the definition paragraphs that support the naming of cell-based substances.
Charles River says the combination of Distributed Bio’s platform, which the CRO recently acquired, with its own downstream characterization capabilities, enables identification of the best lead candidate in CAR T cell therapies – balancing efficacy and...
Kite says a two-year retrospective analysis of the commercial manufacturing and supply of its CAR T therapy, axicabtagene ciloleucel (Yescarta), shows a high manufacturing success rate and a reliable turnaround time.
